PFE reported Q1 earnings Tuesday and handily beat expectations.
Both stocks have been underperformers.
The stock of the health plan provider has not been able to show any sustained strength.
Bristol-Myers offers a terrific combination of yield, dividend safety, and dividend growth for income-focused investors.
Here are our price objectives.
Let's take a look at 2 charts.
We're now expecting further strength.
Large purchases of Cortexyme Inc. and NantHealth Inc. shares have been made by insiders recently.
Here's where traders should look to buy a pullback.
Traders could go long CI at current levels, and we have two price objectives.